Exploring High Growth Tech Stocks In November 2024

As global markets experience broad-based gains with U.S. indexes approaching record highs, smaller-cap stocks have notably outperformed their larger counterparts, buoyed by positive sentiment from strong labor market data and rising home sales. In this favorable environment for high-growth tech stocks, investors often seek companies with robust innovation potential and the ability to adapt swiftly to evolving technological demands and economic conditions.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Material Group	20.45%	24.01%	★★★★★★
Pharma Mar	25.97%	56.89%	★★★★★★
Ascelia Pharma	76.15%	47.16%	★★★★★★
Waystream Holding	22.46%	109.25%	★★★★★★
JNTC	20.52%	57.26%	★★★★★★
TG Therapeutics	34.66%	56.48%	★★★★★★
Elliptic Laboratories	65.73%	103.55%	★★★★★★
Alkami Technology	21.89%	98.60%	★★★★★★
Alnylam Pharmaceuticals	22.45%	70.66%	★★★★★★
Travere Therapeutics	31.70%	72.51%	★★★★★★

Click here to see the full list of 1300 stocks from our High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

NCSOFT (KOSE:A036570)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: NCSOFT Corporation is a global developer and publisher of online games, with a market cap of ₩4.33 trillion.

Operations: The company generates revenue primarily through the development and publishing of online games, with a notable focus on global markets. It operates within the gaming industry, leveraging its expertise to create engaging digital experiences for users worldwide.

Despite a challenging year with a 17.5% decline in earnings, NCSOFT is poised for recovery, expecting an impressive 39.6% annual earnings growth over the next three years compared to the South Korean market's 28.4%. This growth trajectory is underscored by a robust revenue forecast of 11.1% annually, surpassing the market average of 9.4%. These figures reflect NCSOFT's strategic focus on innovation and expansion in dynamic sectors like online gaming and digital entertainment, even as they navigate short-term setbacks evident from their recent quarterly losses where sales dropped to KRW 360 billion from KRW 386 billion year-over-year and net losses reached KRW 26.5 billion compared to prior profits of KRW 43.6 billion.

• Click here to discover the nuances of NCSOFT with our detailed analytical health report.

• Evaluate NCSOFT's historical performance by accessing our past performance report.

BYD Electronic (International) (SEHK:285)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BYD Electronic (International) Company Limited is an investment holding company that focuses on designing, manufacturing, assembling, and selling mobile handset components and modules both in China and internationally, with a market capitalization of HK$77.06 billion.

Operations: The company generates revenue primarily through the manufacture, assembly, and sale of mobile handset components and modules, with reported sales reaching CN¥152.36 billion. Its operations extend both within China and internationally.

With a robust 12.5% annual revenue growth rate, BYD Electronic (International) outpaces the Hong Kong market average of 7.8%. This growth is propelled by significant R&D investments, which have not only fueled a 24.5% expected annual earnings increase but also led to innovations that keep them competitive in tech-intensive sectors. These financial indicators highlight the company's strategic emphasis on development and market expansion, despite broader economic pressures that might affect lesser-prepared firms in the industry. Their recent presentations at high-profile conferences and forthcoming earnings reports suggest an ongoing commitment to transparency and growth, aligning with investor interests for forward-looking tech enterprises.

• Click here and access our complete health analysis report to understand the dynamics of BYD Electronic (International).

• Gain insights into BYD Electronic (International)'s historical performance by reviewing our past performance report.

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of novel drugs to address unmet medical needs in China and internationally, with a market cap of HK$37.44 billion.

Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to CN¥1.88 billion. It focuses on developing and commercializing innovative drugs to meet unmet medical needs both domestically and internationally.

Sichuan Kelun-Biotech Biopharmaceutical has shown a promising trajectory with a 24.2% annual revenue growth, outstripping the Hong Kong market average significantly. This growth is underpinned by strategic R&D investments amounting to 3.9% of their revenue, emphasizing their commitment to innovation in drug development for advanced solid tumors and other serious ailments. Recent approvals for clinical trials and partnerships with major industry players like MSD underscore its potential in transforming cancer treatment landscapes, further buoyed by milestone payments and sales royalties that could enhance future financial stability.

• Delve into the full analysis health report here for a deeper understanding of Sichuan Kelun-Biotech Biopharmaceutical.

• Assess Sichuan Kelun-Biotech Biopharmaceutical's past performance with our detailed historical performance reports.

Seize The Opportunity

• Investigate our full lineup of 1300 High Growth Tech and AI Stocks right here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com